Management of Cancer-associated Thrombosis (CAT): Symptomatic or Incidental.

Female Hemorrhage / etiology Humans Male Middle Aged Neoplasm Recurrence, Local / pathology Neoplasms / complications Risk Factors Thrombosis / etiology

CAT LMWH Thrombosis cancer-associated thrombosis incidental CAT low molecular weight heparin symptomatic CAT

Journal

Anticancer research

ISSN: 1791-7530

Titre abrégé: Anticancer Res

Pays: Greece

ID NLM: 8102988

Informations de publication

Date de publication:
Jan 2020

Historique:

received: 05 11 2019

revised: 20 11 2019

accepted: 25 11 2019

entrez: 2 1 2020

pubmed: 2 1 2020

medline: 11 1 2020

Statut: ppublish

Résumé

Cancer-associated thrombosis (CAT), the second leading cause of death in patients with cancer can be treated with low molecular weight heparin (LMWH) according to guidelines. A multicenter prospective observational study was carried out to record anti-thrombotic treatment practice, assess thrombosis recurrence and bleeding, and identify potential risk factors. Adult patients from 18 Oncology Departments throughout Greece were followed-up for 12 months. A total of 120 patients with CAT receiving anticoagulant treatment were enrolled (35% incidental); 85% were treated for more than 6 months, 95.8% were treated with tinzaparin and smaller percentages with other agents. Thrombosis recurred in three patients and there was minor bleeding in four patients. Bleeding was associated with high body mass index (>35 kg/m Incidental thrombosis contributes significantly to CAT burden. Long-term use of LMWH seems to be effective and safe. Several risk factors associated with bleeding should be considered during anti-coagulation therapy planning.

Sections du résumé

BACKGROUND BACKGROUND

Cancer-associated thrombosis (CAT), the second leading cause of death in patients with cancer can be treated with low molecular weight heparin (LMWH) according to guidelines.

PATIENTS AND METHODS METHODS

A multicenter prospective observational study was carried out to record anti-thrombotic treatment practice, assess thrombosis recurrence and bleeding, and identify potential risk factors. Adult patients from 18 Oncology Departments throughout Greece were followed-up for 12 months.

RESULTS RESULTS

A total of 120 patients with CAT receiving anticoagulant treatment were enrolled (35% incidental); 85% were treated for more than 6 months, 95.8% were treated with tinzaparin and smaller percentages with other agents. Thrombosis recurred in three patients and there was minor bleeding in four patients. Bleeding was associated with high body mass index (>35 kg/m

CONCLUSION CONCLUSIONS

Incidental thrombosis contributes significantly to CAT burden. Long-term use of LMWH seems to be effective and safe. Several risk factors associated with bleeding should be considered during anti-coagulation therapy planning.

Identifiants

DOI: 10.21873/anticanres.13954 PMID: 31892581

pubmed: 31892581

pii: 40/1/305

doi: 10.21873/anticanres.13954

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

305-313